person · Reporting owner

SEIDENBERG BETH C

Disclosed activity across 11 companies

Tapewire entity: 13954
SEC CIK: 0001184592

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Atara Biotherapeutics, Inc.ATRA · Entity 6828	Director	May 31, 2023	June 03, 2023
Epizyme, Inc.EPZM · Entity 12703	Director	June 30, 2019	July 02, 2019
Kyverna Therapeutics, Inc.KYTX · Entity 5452	Director	May 27, 2026	May 29, 2026
Latigo Biotherapeutics, Inc.LTGO · Entity 4709	Director · 10% owner	August 10, 2026	August 11, 2026
Progyny, Inc.PGNY · Entity 4521	Director	May 23, 2024	May 29, 2024
Sagimet Biosciences Inc.SGMT · Entity 5273	Director	June 12, 2026	June 15, 2026
Vera Therapeutics, Inc.VERA · Entity 4358	Director	May 21, 2026	May 26, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Atara Biotherapeutics, Inc.

Report date May 31, 2023 · Filed June 03, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	115,689	Reported balance After 2023-05-31 transaction · row 1 1 source row Row 1 · 2023-05-31 · Grant · Acquired 57,000 · Balance 115,689 F1: These restricted stock units shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2033-05-30	Direct	79,500	Reported balance After 2023-05-31 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-05-31 · Grant · Acquired 79,500 · Balance 79,500 F2: The option shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,822,228	Reported balance Holding disclosure · report date 2023-05-31 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,822,228 F3: The shares are directly held by Kleiner Perkins Caufield & Byers XV, LLC ("KPCB XV"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV is KPCB XV Associates, LLC ("XV Associates"). The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power.
Common StockSEC Table I · non-derivative	IndirectSee footnote	54,422	Reported balance Holding disclosure · report date 2023-05-31 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 54,422 F4: The shares are directly held by KPCB XV Founders Fund, LLC ("KPCB XV FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV FF is XV Associates. The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power.
Common StockSEC Table I · non-derivative	IndirectSee footnote	197	Reported balance Holding disclosure · report date 2023-05-31 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 197 F5: Shares held by the Michael J. Seidenberg Irrevocable Trust, established July 1, 2013, of which the Reporting Person is a trustee.
Common StockSEC Table I · non-derivative	IndirectSee footnote	197	Reported balance Holding disclosure · report date 2023-05-31 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 197 F6: Shares held by the Samuel B. Seidenberg Irrevocable Trust, established July 1, 2013, of which the Reporting Person is a trustee.

Filing footnotes · ownership attribution and instrument terms

F1: These restricted stock units shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

F2: The option shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

F3: The shares are directly held by Kleiner Perkins Caufield & Byers XV, LLC ("KPCB XV"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV is KPCB XV Associates, LLC ("XV Associates"). The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power.

F4: The shares are directly held by KPCB XV Founders Fund, LLC ("KPCB XV FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV FF is XV Associates. The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power.

F5: Shares held by the Michael J. Seidenberg Irrevocable Trust, established July 1, 2013, of which the Reporting Person is a trustee.

F6: Shares held by the Samuel B. Seidenberg Irrevocable Trust, established July 1, 2013, of which the Reporting Person is a trustee.

Epizyme, Inc.

Report date June 30, 2019 · Filed July 02, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001SEC Table I · non-derivative	Direct	8,481	Reported balance After 2019-06-30 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2019-06-30 · Grant · Acquired 1,010 · Balance 8,481 F1: The shares were issued to the Reporting Person pursuant to her election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $12,687.50 for Board services for the second fiscal quarter of 2019. The shares were issued on the last day of the second fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter.
Common Stock, par value $0.0001SEC Table I · non-derivative	IndirectSee Notes 2 and 3	4,115,555	Reported balance Holding disclosure · report date 2019-06-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 4,115,555 F2: The shares consist of 3,838,167 shares of common stock held by Kleiner Perkins Caufield & Byers XIII, LLC ("KPCB XIII") and 277,388 shares of common stock beneficially owned by individuals and entities associated with Kleiner Perkins Caulfield & Byers (collectively, "KPCB Direct"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee," for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares. The managing member of KPCB XIII is KPCB XIII Associates, LLC, which has sole voting and dispositive power over the shares held by KPCB XIII. The Reporting Person disclaims beneficial ownership of all shares held by KPCB XIII except to the extent of her pecuniary interest therein. F3: The Reporting Person disclaims beneficial ownership over all Issuer shares held for convenience in the name of "KPCB Holdings, Inc. as nominee," except to the extent of her pecuniary interest therein and this filing is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were issued to the Reporting Person pursuant to her election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $12,687.50 for Board services for the second fiscal quarter of 2019. The shares were issued on the last day of the second fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter.

F2: The shares consist of 3,838,167 shares of common stock held by Kleiner Perkins Caufield & Byers XIII, LLC ("KPCB XIII") and 277,388 shares of common stock beneficially owned by individuals and entities associated with Kleiner Perkins Caulfield & Byers (collectively, "KPCB Direct"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee," for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares. The managing member of KPCB XIII is KPCB XIII Associates, LLC, which has sole voting and dispositive power over the shares held by KPCB XIII. The Reporting Person disclaims beneficial ownership of all shares held by KPCB XIII except to the extent of her pecuniary interest therein.

F3: The Reporting Person disclaims beneficial ownership over all Issuer shares held for convenience in the name of "KPCB Holdings, Inc. as nominee," except to the extent of her pecuniary interest therein and this filing is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.

Kyverna Therapeutics, Inc.

Report date May 27, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	21,727	Reported balance After 2026-05-27 transaction · row 1 1 source row Row 1 · 2026-05-27 · Grant · Acquired 5,093 · Balance 21,727 F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.59 · Expires 2036-05-27	Direct	20,582	Reported balance After 2026-05-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-27 · Grant · Acquired 20,582 · Balance 20,582 F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,787,940	Reported balance Holding disclosure · report date 2026-05-27 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,787,940 F3: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The Reporting Person is the managing director of Westlake GP I and has sole voting and dispositive control over Westlake GP I, and disclaims beneficial ownership of the shares held by Westlake I except to the extent of the Reporting Person's pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	869,317	Reported balance Holding disclosure · report date 2026-05-27 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 869,317 F4: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The Reporting Person is the managing director of Westlake Opportunity GP I and has sole voting and dispositive control over Westlake Opportunity GP I, and disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of the Reporting Person's pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

F3: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The Reporting Person is the managing director of Westlake GP I and has sole voting and dispositive control over Westlake GP I, and disclaims beneficial ownership of the shares held by Westlake I except to the extent of the Reporting Person's pecuniary interest therein, if any.

F4: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The Reporting Person is the managing director of Westlake Opportunity GP I and has sole voting and dispositive control over Westlake Opportunity GP I, and disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of the Reporting Person's pecuniary interest therein, if any.

Latigo Biotherapeutics, Inc.

Report date August 10, 2026 · Filed August 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,368,532	Reported balance After 2026-08-10 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-08-10 · Conversion · Acquired 938,979 · Balance 1,368,532 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting Person is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,916,374	Reported balance After 2026-08-10 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-08-10 · Conversion · Acquired 3,547,842 · Balance 4,916,374 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting Person is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	5,944,009	Reported balance After 2026-08-10 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-08-10 · Conversion · Acquired 1,027,635 · Balance 5,944,009 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting Person is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,510,927	Reported balance After 2026-08-10 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-08-10 · Conversion · Acquired 3,464,072 · Balance 3,510,927 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting Person is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,995,328	Reported balance After 2026-08-10 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2026-08-10 · Conversion · Acquired 1,484,401 · Balance 4,995,328 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting Person is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	5,160,847	Reported balance After 2026-08-10 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2026-08-10 · Conversion · Acquired 165,519 · Balance 5,160,847 F4: Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F3: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting Person is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,094,813	Reported balance After 2026-08-10 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2026-08-10 · Conversion · Acquired 2,066,857 · Balance 2,094,813 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F5: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (Opportunity Fund). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC (Opportunity GP). Opportunity GP may be deemed to share voting and dispositive power with regard to the shares held directly by Opportunity Fund. The Reporting Person is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Series Seed Convertible StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-08-10 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-08-10 · Conversion · Disposed 938,979 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting Person is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-08-10 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-08-10 · Conversion · Disposed 3,547,842 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting Person is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-08-10 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-08-10 · Conversion · Disposed 1,027,635 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting Person is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-08-10 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-08-10 · Conversion · Disposed 3,464,072 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting Person is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-08-10 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-08-10 · Conversion · Disposed 2,066,857 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F5: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (Opportunity Fund). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC (Opportunity GP). Opportunity GP may be deemed to share voting and dispositive power with regard to the shares held directly by Opportunity Fund. The Reporting Person is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-08-10 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-08-10 · Conversion · Disposed 1,484,401 · Balance 0 F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting Person is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
Convertible Promissory NoteSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2026-08-10 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-08-10 · Conversion · Disposed 165,519 · Balance 0 F4: Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F3: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting Person is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

F2: Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. The Reporting Person is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.

F3: Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. The Reporting Person is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.

F4: Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock.

F5: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (Opportunity Fund). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC (Opportunity GP). Opportunity GP may be deemed to share voting and dispositive power with regard to the shares held directly by Opportunity Fund. The Reporting Person is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.

Progyny, Inc.

Report date May 23, 2024 · Filed May 29, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	43,416	Reported balance After 2024-05-23 transaction · row 1 1 source row Row 1 · 2024-05-23 · Grant · Acquired 7,206 · Balance 43,416 F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 23, 2025, subject to the Reporting Person's continued service on such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.15 · Expires 2034-05-22	Direct	26,926	Reported balance After 2024-05-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-05-23 · Grant · Acquired 26,926 · Balance 26,926 F4: The shares subject to the option will vest on May 23, 2025, subject to the Reporting Person's continued service on such date.
Common StockSEC Table I · non-derivative	IndirectSee footnote	5,074,615	Reported balance Holding disclosure · report date 2024-05-23 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 5,074,615 F2: These shares are held directly by KPCB XIII and individuals and entities associated with KPCB. All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee." The managing member of KPCB XIII is KPCB XIII Associates, LLC ("XIII Associates"). Voting and dispositive control over the shares are shared by individual managing directors of XIII Associates, none of whom have veto power. The Reporting Person disclaims beneficial ownership of all shares held by KPCB XIII except to the extent of the Reporting Person's pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	227,906	Reported balance Holding disclosure · report date 2024-05-23 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 227,906 F3: These shares are held by The Seidenberg/Vogel Revocable Trust u/a/d 3/6/03, as amended and restated on 6/16/2020. Paul S. Vogel and Beth C. Seidenberg are the trustees of the trust.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 23, 2025, subject to the Reporting Person's continued service on such date.

F2: These shares are held directly by KPCB XIII and individuals and entities associated with KPCB. All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee." The managing member of KPCB XIII is KPCB XIII Associates, LLC ("XIII Associates"). Voting and dispositive control over the shares are shared by individual managing directors of XIII Associates, none of whom have veto power. The Reporting Person disclaims beneficial ownership of all shares held by KPCB XIII except to the extent of the Reporting Person's pecuniary interest therein.

F3: These shares are held by The Seidenberg/Vogel Revocable Trust u/a/d 3/6/03, as amended and restated on 6/16/2020. Paul S. Vogel and Beth C. Seidenberg are the trustees of the trust.

F4: The shares subject to the option will vest on May 23, 2025, subject to the Reporting Person's continued service on such date.

Sagimet Biosciences Inc.

Report date June 12, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.48 · Expires 2036-06-11	Direct	39,567	Reported balance After 2026-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-12 · Grant · Acquired 39,567 · Balance 39,567 F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.

Vera Therapeutics, Inc.

Report date May 21, 2026 · Filed May 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20	Direct	17,084	Reported balance After 2026-05-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084 F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACELYRIN, Inc.

Report date May 21, 2025 · Filed May 23, 2025

Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-05-21 transaction · row 1 1 source row Row 1 · 2025-05-21 · Disposition to issuer · Disposed 60,000 · Balance 0 F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2025-05-21 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-05-21 · Disposition to issuer · Disposed 9,790,729 · Balance 0 F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F2: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person is the Managing Director of Westlake GP II and has sole voting and dispositive power over the shares held by Westlake Fund II, and disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of the Reporting Person's pecuniary interest therein, if any.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03	Direct	Reported balance After 2025-05-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-05-21 · Disposition to issuer · Disposed 23,243 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F3: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2034-06-06	Direct	Reported balance After 2025-05-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-05-21 · Disposition to issuer · Disposed 92,158 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F5: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.

F2: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person is the Managing Director of Westlake GP II and has sole voting and dispositive power over the shares held by Westlake Fund II, and disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of the Reporting Person's pecuniary interest therein, if any.

F3: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F4: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.

F5: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.

AMGEN INC

Report date December 31, 2004 · Filed January 04, 2005

Section 16 reporting ended · disclosed 2005-01-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	15,343	Ending reported balance After 2004-12-31 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2004-12-31 · Tax withholding · Disposed 6,121 · Balance 20,720 Row 2 · 2004-12-31 · Disposition to issuer · Disposed 5,377 · Balance 15,343

ARMO BioSciences, Inc.

Report date June 22, 2018 · Filed June 22, 2018

Section 16 reporting ended · disclosed 2018-06-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy KPCB Holdings, Inc., as nominee	0	Reported balance After 2018-06-22 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2018-06-22 · Other · Disposed 4,266,683 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F4: Consists of 3,475,576 shares of common stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates"). F5: (Continued from Footnote 4) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.97 · Expires 2028-03-25	Direct	0	Reported balance After 2018-06-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-06-22 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share.

F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.

F3: This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F4: Consists of 3,475,576 shares of common stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates").

F5: (Continued from Footnote 4) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF.

TESARO, Inc.

Report date January 22, 2019 · Filed January 24, 2019

Section 16 reporting ended · disclosed 2019-01-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-01-22 transaction · row 1 1 source row Row 1 · 2019-01-22 · Other · Disposed 45,907 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
Common StockSEC Table I · non-derivative	IndirectSee footnotes	Reported balance After 2019-01-22 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-01-22 · Other · Disposed 1,994,768 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F2: The shares are held directly by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"). The managing member of KPCB XIV is KPCB XIV Associates, LLC ("KPCB XIV Associates"), of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee." F3: The Reporting Person disclaims beneficial ownership over all TESARO shares held for convenience in the name of "KPCB Holdings, Inc., as nominee," except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnotes	Reported balance After 2019-01-22 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2019-01-22 · Other · Disposed 168,755 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F3: The Reporting Person disclaims beneficial ownership over all TESARO shares held for convenience in the name of "KPCB Holdings, Inc., as nominee," except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. F4: The shares are held directly by KPCB XIV Founders Fund, LLC ("KPCB XIV Founders"). The managing member of KPCB XIV Founders is KPCB XIV Associates, of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee."
Common StockSEC Table I · non-derivative	IndirectSee footnotes	Reported balance After 2019-01-22 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2019-01-22 · Other · Disposed 10,998 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F3: The Reporting Person disclaims beneficial ownership over all TESARO shares held for convenience in the name of "KPCB Holdings, Inc., as nominee," except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. F5: The shares are held directly by KPCB XIV Associates, of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee."
Common StockSEC Table I · non-derivative	IndirectBy Michael J. Seidenberg Irrevocable Trust	Reported balance After 2019-01-22 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2019-01-22 · Other · Disposed 868 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F6: The Reporting Person and her spouse are co-trustees of the trust and their son is beneficiary of the trust. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Michael J. Seidenberg Irrevocable Trust	Reported balance After 2019-01-22 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2019-01-22 · Other · Disposed 868 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F6: The Reporting Person and her spouse are co-trustees of the trust and their son is beneficiary of the trust. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
Director Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-01-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-01-22 · Disposition to issuer · Disposed 4,052 · Balance 0 F7: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F8: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.22 · Expires 2023-06-03	Direct	Reported balance After 2019-01-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-01-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F9: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F10: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.36 · Expires 2024-06-01	Direct	Reported balance After 2019-01-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-01-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F9: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F10: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.77 · Expires 2025-06-01	Direct	Reported balance After 2019-01-22 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-01-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F9: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F10: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.27 · Expires 2026-06-01	Direct	Reported balance After 2019-01-22 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2019-01-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F9: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F10: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.22 · Expires 2027-06-01	Direct	Reported balance After 2019-01-22 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2019-01-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F9: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F10: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.89 · Expires 2028-06-01	Direct	Reported balance After 2019-01-22 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2019-01-22 · Disposition to issuer · Disposed 7,209 · Balance 0 F9: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F10: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Filing footnotes · ownership attribution and instrument terms

F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").

F2: The shares are held directly by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"). The managing member of KPCB XIV is KPCB XIV Associates, LLC ("KPCB XIV Associates"), of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee."

F3: The Reporting Person disclaims beneficial ownership over all TESARO shares held for convenience in the name of "KPCB Holdings, Inc., as nominee," except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.

F4: The shares are held directly by KPCB XIV Founders Fund, LLC ("KPCB XIV Founders"). The managing member of KPCB XIV Founders is KPCB XIV Associates, of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee."

F5: The shares are held directly by KPCB XIV Associates, of which the Reporting Person is a member. The voting and dispositive control over the shares is shared by the members of KPCB XIV Associates. The shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee."

F6: The Reporting Person and her spouse are co-trustees of the trust and their son is beneficiary of the trust. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of her pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.

F7: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.

F8: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.

F9: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]

F10: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 18, 2023 Filed Jul 20, 2023 20:20 UTC	Sagimet Biosciences Inc. SGMT · Entity 5273	ConversionSeries C Preferred Stock · Derivative	8,596,589	$0.00	$0.00	Disclosure SEC source: 0001104659-23-082736 · tm2321276-23_4seq1.xml · derivative · entry 9 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Series A Common Stock · 108,163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F3 · kind: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:20 UTC	Sagimet Biosciences Inc. SGMT · Entity 5273	ConversionSeries B-1 Preferred Stock · Derivative	8,596,590	$0.00	$0.00	Disclosure SEC source: 0001104659-23-082736 · tm2321276-23_4seq1.xml · derivative · entry 8 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Series A Common Stock · 108,163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F3 · kind: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:20 UTC	Sagimet Biosciences Inc. SGMT · Entity 5273	ConversionSeries B Preferred Stock · Derivative	493,370	$0.00	$0.00	Disclosure SEC source: 0001104659-23-082736 · tm2321276-23_4seq1.xml · derivative · entry 7 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Series A Common Stock · 6,208 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F3 · kind: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:20 UTC	Sagimet Biosciences Inc. SGMT · Entity 5273	ConversionSeries A Preferred Stock · Derivative	539,006	$0.00	$0.00	Disclosure SEC source: 0001104659-23-082736 · tm2321276-23_4seq1.xml · derivative · entry 6 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Series A Common Stock · 6,781 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F3 · kind: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:20 UTC	Sagimet Biosciences Inc. SGMT · Entity 5273	PurchaseSeries A Common Stock	46,875	$16.00	$750,000.00	Disclosure SEC source: 0001104659-23-082736 · tm2321276-23_4seq1.xml · nonDerivative · entry 5 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 46,875 F5 · ownership.nature: Shares held by the Seidenberg/Vogel Revocable Trust UA 3/6/03, of which the Reporting Person serves as a trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:20 UTC	Sagimet Biosciences Inc. SGMT · Entity 5273	ConversionSeries A Common Stock	84,768	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-082736 · tm2321276-23_4seq1.xml · nonDerivative · entry 4 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F3 · price: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F4 · ownership.direct: Shares held directly by the Reporting Person. Such shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:20 UTC	Sagimet Biosciences Inc. SGMT · Entity 5273	ConversionSeries A Common Stock	1,860,712	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-082736 · tm2321276-23_4seq1.xml · nonDerivative · entry 3 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,899,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F3 · price: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:20 UTC	Sagimet Biosciences Inc. SGMT · Entity 5273	GrantSeries A Common Stock	38,763	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-082736 · tm2321276-23_4seq1.xml · nonDerivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 38,763 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F1 · price: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · ownership.nature: Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:20 UTC	Sagimet Biosciences Inc. SGMT · Entity 5273	Disposition to issuerCommon Stock	38,763	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-082736 · tm2321276-23_4seq1.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F1 · price: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · ownership.nature: Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document
June 23, 2023 Filed Jun 27, 2023 20:57 UTC	Progyny, Inc. PGNY · Entity 4521	OtherCommon Stock	10,284	$0.00	$0.00	Disclosure SEC source: 0001628280-23-023606 · wf-form4_168789945447142.xml · nonDerivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,210 F3 · kind: Represents a change in the form of ownership as a result of the receipt by the Reporting Person of shares in the Fund Distribution. Read SEC document
June 23, 2023 Filed Jun 27, 2023 20:57 UTC	Progyny, Inc. PGNY · Entity 4521	OtherCommon Stock	17,162	$0.00	$0.00	Disclosure SEC source: 0001628280-23-023606 · wf-form4_168789945447142.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by KPCB XIII Associates, LLC ("XIII Associates") without consideration to its members ("Fund Distribution"). F2 · ownership.nature: Held directly by XIII Associates. Read SEC document
June 09, 2023 Filed Jun 14, 2023 01:20 UTC	Progyny, Inc. PGNY · Entity 4521	OtherCommon Stock	6,656	$0.00	$0.00	Disclosure SEC source: 0001628280-23-022017 · wf-form4_168670559137775.xml · nonDerivative · entry 4 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,926 F7 · kind: Represents a change in the form of ownership as a result of the receipt by XIII Associates of shares in the Fund Distribution. Read SEC document
June 09, 2023 Filed Jun 14, 2023 01:20 UTC	Progyny, Inc. PGNY · Entity 4521	OtherCommon Stock	247,446	$0.00	$0.00	Disclosure SEC source: 0001628280-23-022017 · wf-form4_168670559137775.xml · nonDerivative · entry 3 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 17,162 F5 · kind: Represents a pro-rata in-kind distribution of common stock of the Issuer by XIII Associates without consideration to its members. F6 · ownership.nature: Consists of 17,162 shares of common stock of the Issuer held by XIII Associates. Read SEC document
June 09, 2023 Filed Jun 14, 2023 01:20 UTC	Progyny, Inc. PGNY · Entity 4521	OtherCommon Stock	264,608	$0.00	$0.00	Disclosure SEC source: 0001628280-23-022017 · wf-form4_168670559137775.xml · nonDerivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 264,608 F3 · kind: Represents a change in the form of ownership as a result of the receipt by XIII Associates of shares in the Fund Distribution. F4 · ownership.nature: Consists of 264,608 shares of common stock of the Issuer held by XIII Associates. Read SEC document
June 09, 2023 Filed Jun 14, 2023 01:20 UTC	Progyny, Inc. PGNY · Entity 4521	OtherCommon Stock	1,398,900	$0.00	$0.00	Disclosure SEC source: 0001628280-23-022017 · wf-form4_168670559137775.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,074,615 F1 · kind: Represents a pro-rata in-kind distribution of common stock of the Issuer by Kleiner Perkins Caufield & Byers XIII, LLC ("KPCB XIII") without consideration to its members (the "Fund Distribution"). Excludes 101,100 shares of common stock for which a change in the form of beneficial ownership for individuals and entities associated with Kleiner Perkins Caufield & Byers occurred. F2 · ownership.nature: The shares are directly held by KPCB XIII. All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee." The managing member of KPCB XIII is KPCB XIII Associates, LLC ("XIII Associates"). The voting and dispositive control over the shares is shared by individual managing directors of XIII Associates, none of whom has veto power. Excludes 366,748 shares of common stock beneficially owned by individuals and entities associated with Kleiner Perkins Caufield & Byers and held for convenience in the name of "KPCB Holdings, Inc. as nominee," for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares. Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:06 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	79,500	$0.00 Strike: $1.53	$0.00	Disclosure SEC source: 0001140361-23-028161 · form4.xml · derivative · entry 6 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,500 Underlying: Common Stock · 79,500 shares Expires 2033-05-30 F2 · derivative.exercise_date: The option shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:06 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantCommon Stock	57,000	$0.00	$0.00	Disclosure SEC source: 0001140361-23-028161 · form4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,689 F1 · shares: These restricted stock units shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
May 24, 2023 Filed Jun 1, 2023 20:20 UTC	Progyny, Inc. PGNY · Entity 4521	GrantStock Option (Right to Buy) · Derivative	3,261	$19.93 Strike: $38.24	$64,991.73	Disclosure SEC source: 0001628280-23-020505 · wf-form4_168565081002134.xml · derivative · entry 5 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,261 Underlying: Common Stock · 3,261 shares Expires 2033-05-23 F5 · price: This option was issued to the Reporting Person in lieu of annual retainers for board and committee service. The shares underlying the option reflect payment of the Reporting Person's annual retainer of $64,984. F4 · derivative.exercise_date: The shares subject to the Option shall vest on May 24, 2024, subject to the Reporting Person continuing to provide service through such date. Read SEC document
May 24, 2023 Filed Jun 1, 2023 20:20 UTC	Progyny, Inc. PGNY · Entity 4521	GrantStock Option (Right to Buy) · Derivative	19,709	$0.00 Strike: $38.24	$0.00	Disclosure SEC source: 0001628280-23-020505 · wf-form4_168565081002134.xml · derivative · entry 4 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,709 Underlying: Common Stock · 19,709 shares Expires 2033-05-23 F4 · derivative.exercise_date: The shares subject to the Option shall vest on May 24, 2024, subject to the Reporting Person continuing to provide service through such date. Read SEC document
May 24, 2023 Filed Jun 1, 2023 20:20 UTC	Progyny, Inc. PGNY · Entity 4521	GrantCommon Stock	5,116	$0.00	$0.00	Disclosure SEC source: 0001628280-23-020505 · wf-form4_168565081002134.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,270 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs shall vest on May 24, 2024, subject to the Reporting Person continuing to provide service through such date. Read SEC document
May 10, 2023 Filed May 12, 2023 20:18 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $7.70	$0.00	Disclosure SEC source: 0001209191-23-029038 · doc4.xml · derivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Class A Common Stock · 20,000 shares Expires 2033-05-09 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document
May 09, 2023 Filed May 12, 2023 01:13 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherDirector Stock Option (right to buy) · Derivative	23,243	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001209191-23-028884 · doc4.xml · derivative · entry 8 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,243 Underlying: Common Stock · 23,243 shares Expires 2033-05-03 F6 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F7 · derivative.exercise_date: 1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F6 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document
May 09, 2023 Filed May 12, 2023 01:13 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherDirector Stock Option (right to buy) · Derivative	23,243	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001209191-23-028884 · doc4.xml · derivative · entry 7 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 23,243 shares Expires 2033-05-03 F6 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F7 · derivative.exercise_date: 1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F6 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document
May 09, 2023 Filed May 12, 2023 01:13 UTC	ACELYRIN, Inc. SLRN · Entity 79310	ConversionSeries C Redeemable Convertible Preferred Stock · Derivative	2,038,148	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-028884 · doc4.xml · derivative · entry 6 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,038,148 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F5 · price: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F5 · derivative.exercise_date: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F5 · derivative.expiration_date: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F6 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any. Read SEC document
May 09, 2023 Filed May 12, 2023 01:13 UTC	ACELYRIN, Inc. SLRN · Entity 79310	ConversionSeries B Redeemable Convertible Preferred Stock · Derivative	2,445,786	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-028884 · doc4.xml · derivative · entry 5 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,445,786 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F5 · price: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F5 · derivative.exercise_date: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F5 · derivative.expiration_date: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F6 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any. Read SEC document
May 09, 2023 Filed May 12, 2023 01:13 UTC	ACELYRIN, Inc. SLRN · Entity 79310	ConversionSeries A Redeemable Convertible Preferred Stock · Derivative	4,056,795	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-028884 · doc4.xml · derivative · entry 4 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 4,056,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F5 · price: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F5 · derivative.exercise_date: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F5 · derivative.expiration_date: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F6 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any. Read SEC document
May 09, 2023 Filed May 12, 2023 01:13 UTC	ACELYRIN, Inc. SLRN · Entity 79310	PurchaseCommon Stock	60,000	$18.00	$1,080,000.00	Disclosure SEC source: 0001209191-23-028884 · doc4.xml · nonDerivative · entry 3 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 F4 · kind: Represents shares of Common Stock purchased through a directed share program in the IPO. Read SEC document
May 09, 2023 Filed May 12, 2023 01:13 UTC	ACELYRIN, Inc. SLRN · Entity 79310	PurchaseCommon Stock	1,250,000	$18.00	$22,500,000.00	Disclosure SEC source: 0001209191-23-028884 · doc4.xml · nonDerivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 9,790,729 F3 · kind: Represents shares of Common Stock purchased in the Issuer's initial public offering of Common Stock (the "IPO"). F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any. Read SEC document
May 09, 2023 Filed May 12, 2023 01:13 UTC	ACELYRIN, Inc. SLRN · Entity 79310	ConversionCommon Stock	8,540,729	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-028884 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,540,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Common Stock received upon conversion of shares of the reported series of preferred stock on a one-for-one basis without payment of further consideration. F1 · price: Represents shares of Common Stock received upon conversion of shares of the reported series of preferred stock on a one-for-one basis without payment of further consideration. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any. Read SEC document
May 04, 2023 Filed May 5, 2023 00:21 UTC	ACELYRIN, Inc. SLRN · Entity 79310	GrantDirector Stock Option (right to buy) · Derivative	23,243	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001209191-23-027537 · doc4.xml · derivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,243 Underlying: Class A Common · 23,243 shares Expires 2033-05-03 F1 · derivative.exercise_date: 1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document
March 30, 2023 Filed Apr 3, 2023 20:05 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	2,300	$7.24	$16,650.85	Disclosure SEC source: 0001209191-23-022150 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,949,295 F1 · shares: The shares were purchased as follows: 2,224 shares by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 76 shares by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F2 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $7.23 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: Consists of 1,884,776 shares of Class A Common Stock held by KPCB XVI and 64,519 shares of Class A Common Stock held by XVI Founders. Read SEC document
March 28, 2023 Filed Mar 30, 2023 20:07 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	23,908	$7.24	$173,191.94	Disclosure SEC source: 0001209191-23-021609 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,946,995 F1 · shares: The shares were purchased as follows: 23,117 shares by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 791 shares by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F2 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $7.18 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: Consists of 1,882,552 shares of Class A Common Stock held by KPCB XVI and 64,443 shares of Class A Common Stock held by XVI Founders. Read SEC document
March 27, 2023 Filed Mar 28, 2023 20:05 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	1,633	$7.24	$11,830.27	Disclosure SEC source: 0001209191-23-021386 · doc4.xml · nonDerivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,923,087 F4 · shares: The shares were purchased as follows: 1,579 shares by KPCB XVI and 54 shares by XVI Founders. All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is XVI Associates. L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F5 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $7.23 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F6 · ownership.nature: Consists of 1,859,435 shares of Class A Common Stock held by KPCB XVI and 63,652 shares of Class A Common Stock held by XVI Founders. Read SEC document
March 24, 2023 Filed Mar 28, 2023 20:05 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	1,833	$7.24	$13,271.84	Disclosure SEC source: 0001209191-23-021386 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,921,454 F1 · shares: The shares were purchased as follows: 1,772 shares by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 61 shares by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F2 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $7.20 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: Consists of 1,857,856 shares of Class A Common Stock held by KPCB XVI and 63,598 shares of Class A Common Stock held by XVI Founders. Read SEC document
March 20, 2023 Filed Mar 21, 2023 20:40 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	15,252	$7.21	$110,032.50	Disclosure SEC source: 0001209191-23-020280 · doc4.xml · nonDerivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,919,621 F4 · shares: The shares were purchased as follows: 14,747 shares by KPCB XVI and 505 shares by XVI Founders. All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is XVI Associates. L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F5 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $7.14 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F6 · ownership.nature: Consists of 1,856,084 shares of Class A Common Stock held by KPCB XVI and 63,537 shares of Class A Common Stock held by XVI Founders. Read SEC document
March 17, 2023 Filed Mar 21, 2023 20:40 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	74,045	$7.12	$526,882.01	Disclosure SEC source: 0001209191-23-020280 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,904,369 F1 · shares: The shares were purchased as follows: 71,594 shares by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 2,451 shares by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F2 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $6.96 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: Consists of 1,841,337 shares of Class A Common Stock held by KPCB XVI and 63,032 shares of Class A Common Stock held by XVI Founders. Read SEC document
March 16, 2023 Filed Mar 17, 2023 20:10 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	60,097	$7.09	$426,268.02	Disclosure SEC source: 0001209191-23-019611 · doc4.xml · nonDerivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,830,324 F4 · shares: The shares were purchased as follows: 58,108 shares by KPCB XVI and 1,989 shares by XVI Founders. All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is XVI Associates. L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F5 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $6.84 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F6 · ownership.nature: Consists of 1,769,743 shares of Class A Common Stock held by KPCB XVI and 60,581 shares of Class A Common Stock held by XVI Founders. Read SEC document
March 15, 2023 Filed Mar 17, 2023 20:10 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	32,844	$7.12	$234,010.22	Disclosure SEC source: 0001209191-23-019611 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,770,227 F1 · shares: The shares were purchased as follows: 31,757 shares by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 1,087 shares by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F2 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $7.08 to $7.15. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: Consists of 1,711,635 shares of Class A Common Stock held by KPCB XVI and 58,592 shares of Class A Common Stock held by XVI Founders. Read SEC document
March 10, 2023 Filed Mar 14, 2023 20:05 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	48,003	$7.16	$343,485.47	Disclosure SEC source: 0001209191-23-018409 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,737,383 F1 · shares: The shares were purchased as follows: 46,414 shares by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 1,589 shares by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F2 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $7.06 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: Consists of 1,679,878 shares of Class A Common Stock held by KPCB XVI and 57,505 shares of Class A Common Stock held by XVI Founders. Read SEC document
March 03, 2023 Filed Mar 7, 2023 21:07 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	1,000	$7.25	$7,245.00	Disclosure SEC source: 0001209191-23-016702 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,689,380 F1 · shares: The shares were purchased as follows: 967 shares by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 33 shares by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F2 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $7.23 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: Consists of 1,633,464 shares of Class A Common Stock held by KPCB XVI and 55,916 shares of Class A Common Stock held by XVI Founders. Read SEC document
March 02, 2023 Filed Mar 3, 2023 21:07 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	23,378	$7.24	$169,322.18	Disclosure SEC source: 0001209191-23-015418 · doc4.xml · nonDerivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,688,380 F3 · shares: The shares were purchased as follows: 22,604 shares by KPCB XVI and 774 shares by XVI Founders. All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is XVI Associates. L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F4 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $7.22 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F5 · ownership.nature: Consists of 1,632,497 shares of Class A Common Stock held by KPCB XVI and 55,883 shares of Class A Common Stock held by XVI Founders. Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:07 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	100	$7.25	$725.00	Disclosure SEC source: 0001209191-23-015418 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,665,002 F1 · shares: The shares were purchased as follows: 97 shares by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 3 shares by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F2 · ownership.nature: Consists of 1,609,893 shares of Class A Common Stock held by KPCB XVI and 55,109 shares of Class A Common Stock held by XVI Founders. Read SEC document
February 23, 2023 Filed Feb 27, 2023 21:07 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	200	$7.24	$1,447.00	Disclosure SEC source: 0001209191-23-013159 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,664,902 F1 · shares: The shares were purchased as follows: 193 shares by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 7 shares by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F2 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $7.22 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: Consists of 1,609,796 shares of Class A Common Stock held by KPCB XVI and 55,106 shares of Class A Common Stock held by XVI Founders. Read SEC document
February 13, 2023 Filed Feb 15, 2023 23:32 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	10,072	$7.20	$72,490.20	Disclosure SEC source: 0001209191-23-009873 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,664,702 F1 · shares: The shares were purchased as follows: 9,739 shares by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 333 shares by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F2 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $7.1096 to $7.2500. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: Consists of 1,609,603 shares of Class A Common Stock held by KPCB XVI and 55,099 shares of Class A Common Stock held by XVI Founders. Read SEC document
February 09, 2023 Filed Feb 13, 2023 21:04 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	400	$7.25	$2,900.00	Disclosure SEC source: 0001209191-23-008685 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,654,630 F1 · shares: The shares were purchased as follows: 387 shares by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 13 shares by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F2 · ownership.nature: Consists of 1,599,864 shares of Class A Common Stock held by KPCB XVI and 54,766 shares of Class A Common Stock held by XVI Founders. Read SEC document
February 08, 2023 Filed Feb 9, 2023 21:36 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	45,357	$7.22	$327,477.54	Disclosure SEC source: 0001209191-23-008025 · doc4.xml · nonDerivative · entry 4 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,654,230 F10 · shares: The shares were purchased as follows: 43,856 by KPCB XVI and 1,501 by XVI Founders. F11 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $7.06 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F12 · ownership.nature: Consists of 1,599,477 shares of Class A Common Stock held by KPCB XVI and 54,753 shares of Class A Common Stock held by XVI Founders. Read SEC document
February 07, 2023 Filed Feb 9, 2023 21:36 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	87,956	$7.08	$622,728.48	Disclosure SEC source: 0001209191-23-008025 · doc4.xml · nonDerivative · entry 3 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,608,873 F7 · shares: The shares were purchased as follows: 85,045 by KPCB XVI and 2,911 by XVI Founders. F8 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $6.97 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F9 · ownership.nature: Consists of 1,555,621 shares of Class A Common Stock held by KPCB XVI and 53,252 shares of Class A Common Stock held by XVI Founders. Read SEC document
February 06, 2023 Filed Feb 9, 2023 21:36 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	131,602	$7.03	$925,162.06	Disclosure SEC source: 0001209191-23-008025 · doc4.xml · nonDerivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,520,917 F4 · shares: The shares were purchased as follows: 127,246 by KPCB XVI and 4,356 by XVI Founders. F5 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $6.86 to $7.24. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F6 · ownership.nature: Consists of 1,470,576 shares of Class A Common Stock held by KPCB XVI and 50,341 shares of Class A Common Stock held by XVI Founders. Read SEC document
February 03, 2023 Filed Feb 9, 2023 21:36 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	46,163	$7.24	$334,220.12	Disclosure SEC source: 0001209191-23-008025 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,389,315 F1 · shares: The shares were purchased as follows: 44,635 by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 1,528 by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. F2 · price: Represents weighted average purchase price. The shares were purchased at prices ranging from $7.21 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: Consists of 1,343,330 shares of Class A Common Stock held by KPCB XVI and 45,985 shares of Class A Common Stock held by XVI Founders. Read SEC document
October 24, 2022 Filed Oct 26, 2022 21:40 UTC	Progyny, Inc. PGNY · Entity 4521	GrantStock Option (Right to Buy) · Derivative	1,898	$0.00 Strike: $38.22	$0.00	Disclosure SEC source: 0001628280-22-027105 · wf-form4_166682038835521.xml · derivative · entry 7 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 Underlying: Common Stock · 1,898 shares Expires 2032-10-23 F5 · price: This option was issued to the Reporting Person in lieu of annual retainers for board and committee service. The shares underlying the option reflect the payment in full of the Reporting Person's annual retainers of $37,749.66. F4 · derivative.exercise_date: The shares subject to the Option shall vest on May 23, 2023, subject to the Reporting Person continuing to provide service through such date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.